DE69941566D1 - N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie - Google Patents

N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie

Info

Publication number
DE69941566D1
DE69941566D1 DE69941566T DE69941566T DE69941566D1 DE 69941566 D1 DE69941566 D1 DE 69941566D1 DE 69941566 T DE69941566 T DE 69941566T DE 69941566 T DE69941566 T DE 69941566T DE 69941566 D1 DE69941566 D1 DE 69941566D1
Authority
DE
Germany
Prior art keywords
acetylhomotaurinates
hyperkinesia
treatment
acetylhomotaurinates use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941566T
Other languages
English (en)
Inventor
Barry S Fogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synchroneuron Inc
Original Assignee
Synchroneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/193,892 external-priority patent/US6294583B1/en
Priority claimed from US09/224,829 external-priority patent/US6057373A/en
Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc
Priority claimed from PCT/US1999/000144 external-priority patent/WO1999036064A2/en
Application granted granted Critical
Publication of DE69941566D1 publication Critical patent/DE69941566D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69941566T 1998-01-13 1999-01-13 N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie Expired - Lifetime DE69941566D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/006,641 US5952389A (en) 1998-01-13 1998-01-13 Methods of treating tardive dyskinesia and other movement disorders
US09/193,892 US6294583B1 (en) 1998-01-13 1998-11-18 Methods of treating tardive dyskinesia and other movement disorders
US09/224,829 US6057373A (en) 1997-05-22 1999-01-04 Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
PCT/US1999/000144 WO1999036064A2 (en) 1998-01-13 1999-01-13 Methods of treating tardive dyskinesia and other movement disorders

Publications (1)

Publication Number Publication Date
DE69941566D1 true DE69941566D1 (de) 2009-12-03

Family

ID=21721892

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941566T Expired - Lifetime DE69941566D1 (de) 1998-01-13 1999-01-13 N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie

Country Status (2)

Country Link
US (1) US5952389A (de)
DE (1) DE69941566D1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
WO2001072311A1 (en) * 2000-03-28 2001-10-04 Delorenzo Robert J Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
US6365618B1 (en) * 2000-12-13 2002-04-02 Conrad M. Swartz Administration of carvedilol to mitigate tardive movement disorders, psychosis, mania, and depression
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
US20030045541A1 (en) * 2001-07-23 2003-03-06 Christopher Bruckner GABA-Receptor modulators with NMDA-Antagonistic activity
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
JP2005314579A (ja) * 2004-04-30 2005-11-10 Nitto Denko Corp 粘着剤組成物、および粘着シート類
JP4917267B2 (ja) * 2004-09-16 2012-04-18 日東電工株式会社 粘着剤組成物、粘着シート類、および表面保護フィルム
JP4531628B2 (ja) * 2004-09-16 2010-08-25 日東電工株式会社 粘着剤組成物、粘着シート類、および表面保護フィルム
WO2006059252A2 (en) * 2004-11-12 2006-06-08 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
US20060167057A1 (en) * 2004-11-16 2006-07-27 Xianqi Kong Compounds for the treatment of CNS and amyloid associated diseases
EP1836161B1 (de) 2004-12-22 2016-07-20 BHI Limited Partnership Verfahren und zusammensetzungen zur behandlung von amyloidassoziierten krankheiten
EP1874353A1 (de) 2005-04-05 2008-01-09 Yale University Glutamat-modulierungsmittel bei der behandlung von geisteserkrankungen
JP5259940B2 (ja) * 2005-09-05 2013-08-07 日東電工株式会社 粘着剤組成物、粘着シートおよび表面保護フィルム
KR20080059208A (ko) * 2005-09-16 2008-06-26 세레우사이언스 아베 수면 호흡 장애를 예방 및 치료하는 방법과 그 수단
DK3851447T3 (da) 2006-10-12 2023-12-04 Bellus Health Inc Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090069419A1 (en) * 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en) * 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
AU2009293164B2 (en) 2008-09-18 2015-07-09 Northwestern University NMDA receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Morbus Parkinson
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20151438A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190502A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH603545A5 (de) * 1972-04-20 1978-08-31 Merz & Co
US4233229A (en) * 1978-01-03 1980-11-11 Gaf Corporation Preparation of salt-free N-acyl taurines
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5262162A (en) * 1991-09-06 1993-11-16 Merz & Co. Gmbh & Co. Cerebral-activating extract
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Also Published As

Publication number Publication date
US5952389A (en) 1999-09-14

Similar Documents

Publication Publication Date Title
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE69736197D1 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE292975T1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60001255T2 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE291916T1 (de) Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
ATE235494T1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition